Subcutaneous and Intravenous Cladribine Treatment of Hairy Cell Leukemia Patients: Do We Still Need Intravenous Cladribine?
Background Hairy cell leukemia (HCL) is an uncommon neoplasm representing approximately 2% leukemias and
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Nizameddin KOCA
2023-04-01
|
| Rangatū: | Turkish Journal of Internal Medicine |
| Urunga tuihono: | https://dergipark.org.tr/en/download/article-file/2907062 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|